Lähteenvuo notes that while more research is called for, drugs like Ozempic may offer hope to those burdened by addiction, “Our study suggests that besides obesity and diabetes, GLP-1-agonists may also help in the treatment of alcohol and substance use disorders; however, these findings need to be further validated in randomized controlled trials.”

A new study has revealed that GLP-1 drugs, commonly used for diabetes and weight loss, show promise in treating alcohol addiction. The research, published in JAMA Psychiatry, found that semaglutide and liraglutide may reduce alcohol cravings by influencing the brain's reward system.

The weight loss drugs Ozempic and Wegovy may be beneficial for people struggling with alcohol addiction, a study published Wednesday in JAMA Psychiatry said. The study examined about 228,000

GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart disease, Parkinson’s, sleep apnea and addiction.

The blockbuster GLP-1 drug semaglutide (Ozempic, Wegovy) could curb drinking for people battling alcohol use disorder, helping them to avoid crises that require hospitalization, new research shows. Numerous studies had already hinted that semaglutide might act on appetite centers in the brain to suppress the urge to drink,

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA Psychiatry suggests.